Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain

Elena Roel, Andrea Pistillo, Martina Recalde, Anthony G. Sena, Sergio Fernández‐Bertolín, María Aragón, Diana Puente, Waheed‐Ul‐Rahman Ahmed, Heba Alghoul, Osaid Alser, Thamir M. Alshammari, Carlos Areia, Clair Blacketer, William Carter, Paula Casajust, Aedín C. Culhane, Dalia Dawoud, Frank DeFalco, Scott L. DuVall, Thomas Falconer, Asieh Golozar, Mengchun Gong, Laura Hester, George Hripcsak, Eng Hooi Tan, Hokyun Jeon, Jitendra Jonnagaddala, Lana Yin Hui Lai, Kristine E. Lynch, Michael E. Matheny, Daniel R. Morales, Karthik Natarajan, Fredrik Nyberg, Anna Ostropolets, Jose Posada, Albert Prats‐Uribe, Christian Reich, Donna R. Rivera, Lisa M. Schilling, Isabelle Soerjomataram, Karishma Shah, Nigam H. Shah, Yang Shen, Matthew Spotniz, Vignesh Subbian, Marc A. Suchard, Annalisa Trama, Lin Zhang, Ying Zhang, Patrick Ryan, Daniel Prieto‐Alhambra, Kristin Kostka, Talita Duarte‐SallesmedRxiv 2021 · DOI

Abstract

This study aimed to describe the demographics, cancer subtypes, comorbidities, and 30-day outcomes of patients with a history of cancer who contracted COVID-19 between March and June 2020. Utilizing eight routinely collected healthcare databases from Spain and the United States, researchers analyzed a cohort of 118,155 patients diagnosed with COVID-19 and 41,939 hospitalized with the virus. These cohorts were compared against a historical benchmark of 242,960 patients hospitalized with influenza in 2017-2018. The findings revealed that while cancer patients with COVID-19 shared similar demographic profiles with influenza patients, they experienced significantly higher rates of mortality (up to 26% in hospitalized cases) and severe complications like Acute Respiratory Distress Syndrome (ARDS). Hematological malignancies were notably frequent among the COVID-19 cohorts, highlighting specific vulnerabilities within the oncological population.

Introduction

Early in the SARS-CoV-2 pandemic, clinical intuition suggested that individuals with a history of cancer were at extreme risk due to potential immunosuppression, frequent healthcare exposure, and advanced age. However, early evidence was often fragmented by small sample sizes or geographic limitations. This study provides a robust, large-scale epidemiological baseline to characterize the risks and outcomes for this vulnerable population across two countries, offering a "benchmark" for the relative virulence of COVID-19 compared to seasonal influenza.

Methodology: Federated Data Analysis

The researchers employed a federated analysis approach through the OHDSI (Observational Health Data Sciences and Informatics) community’s CHARYBDIS project. By utilizing the Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM), the team was able to standardize analytical code and run it locally across eight different healthcare databases in Spain and the US. This method allowed for a massive sample size while maintaining strict patient privacy, as only aggregate, de-identified results were shared centrally.

Datasets

The study utilized a diverse array of data sources:

  • Spain: SIDIAP (primary care data linked to hospitalizations).
  • United States: A combination of Electronic Health Records (EHR) and claims data, including the Department of Veterans Affairs (VA-OMOP), Columbia University Irving Medical Center (CUIMC), Stanford Medicine (STARR-OMOP), and large-scale claims datasets like HealthVerity and IQVIA-OpenClaims.

Key Findings

Patient Profiles and Comorbidities

The study included 118,155 patients diagnosed with COVID-19 and 41,939 hospitalized with the disease. The most frequent cancer subtypes were prostate and breast cancer, reflecting general population prevalence. However, hematological malignancies (such as non-Hodgkin’s lymphoma and leukemia) were surprisingly frequent, appearing among the top five cancer subtypes in the diagnosed cohort.

Beyond their cancer history, these patients presented with a high burden of comorbidities. Hypertension was present in up to 93% of some cohorts, and heart disease and diabetes were also rampant. This suggests that the risk profile for these patients is inextricably tied to a broader state of frailty and multi-morbidity rather than cancer alone.

COVID-19 vs. Influenza

A critical component of the study was the comparison between COVID-19 patients and a historical cohort of 242,960 cancer patients hospitalized with influenza (2017-2018). While the demographics and cancer types were nearly identical between the two groups, the outcomes for COVID-19 patients were significantly more severe.

For example, in the VA-OMOP cohort, mortality was 18% for COVID-19 compared to only 6% for the historical influenza cohort. This confirms that the high mortality observed in cancer patients during the pandemic was driven by the specific virulence of SARS-CoV-2 rather than just the underlying health of the patients.

Clinical Outcomes

The 30-day outcomes for cancer patients with COVID-19 were stark:

  • Mortality: Fatality rates ranged from 8% to 14% for the diagnosed cohort and jumped to 18% to 26% for those hospitalized.
  • Severe Complications: Among hospitalized patients, ARDS occurred in up to 41% of cases, and sepsis was noted in up to 25%.
  • Acute Kidney Injury (AKI): AKI was also a frequent complication, further complicating the clinical management of these patients.

Discussion and Limitations

This observational study provides essential epidemiologic characteristics to inform clinical care. However, the authors acknowledge several limitations. The databases lacked granular details on cancer staging (Stage I vs. IV) and the exact timing of the last oncological treatment. Consequently, it is difficult to distinguish between patients in long-term remission and those undergoing active, intensive therapy. Additionally, because the data stems from real-world clinical coding, there is a potential for underreporting or coding heterogeneity.

Despite these limitations, the scale of the study confirms that patients with a history of cancer and COVID-19 face a high occurrence of severe events. Future research should focus on causal inference, specifically investigating how active treatments like chemotherapy or immunotherapy impact the severity of the viral infection.

Summary updated

Abstract

Abstract Purpose We aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods We conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: i) diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results We included 118,155 patients with a cancer history in the COVID-19 diagnosed and 41,939 in the COVID-19 hospitalized cohorts. The most frequent cancer subtypes were prostate and breast cancer (range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and h ospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events. Conclusion Patients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.
BibTeX
@misc{roel2021characteristics,
  author = {Elena Roel and Andrea Pistillo and Martina Recalde and Anthony G. Sena and Sergio Fernández‐Bertolín and María Aragón and Diana Puente and Waheed‐Ul‐Rahman Ahmed and Heba Alghoul and Osaid Alser and Thamir M. Alshammari and Carlos Areia and Clair Blacketer and William Carter and Paula Casajust and Aedín C. Culhane and Dalia Dawoud and Frank DeFalco and Scott L. DuVall and Thomas Falconer and Asieh Golozar and Mengchun Gong and Laura Hester and George Hripcsak and Eng Hooi Tan and Hokyun Jeon and Jitendra Jonnagaddala and Lana Yin Hui Lai and Kristine E. Lynch and Michael E. Matheny and Daniel R. Morales and Karthik Natarajan and Fredrik Nyberg and Anna Ostropolets and Jose Posada and Albert Prats‐Uribe and Christian Reich and Donna R. Rivera and Lisa M. Schilling and Isabelle Soerjomataram and Karishma Shah and Nigam H. Shah and Yang Shen and Matthew Spotniz and Vignesh Subbian and Marc A. Suchard and Annalisa Trama and Lin Zhang and Ying Zhang and Patrick Ryan and Daniel Prieto‐Alhambra and Kristin Kostka and Talita Duarte‐Salles},
  title = {{Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain}},
  year = {2021},
  doi = {10.1101/2021.01.12.21249672},
  howpublished = {medRxiv},
}
Figure